Galderma S.A. (Switzerland), GlaxoSmithKline plc (U.K.), Valeant Pharmaceuticals International, Inc. (Canada), Crescita Therapeutics Inc. (Canada), Medpharm (U.K.), 3M (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), Janssen Global Services, LLC (U.S.), and Cipla (India) are the prominent players operating in the Topical Drug Delivery Market.

GlaxoSmithKline (GSK) plc is the leading player in this market. The company offers products for various dermatological conditions, such as acne, dermatoses, fungal infections, atopic dermatitis, psoriasis, superficial skin infections, and non-melanoma skin cancer. The company primarily focuses on inorganic growth strategies to strengthen its position in the market. For instance, in 2009, GSK acquired Stiefel Laboratories Inc. (U.S.), a dermatological pharmaceutical company, for USD 2.9 billion. Through this acquisition, GSK combined its existing dermatological products with Stiefel’s products.

Download the PDF Brochure for More Details@ http://bit.ly/2CCSlSZ

Novartis AG is the next leading player in the topical drug delivery market. The company manufactures healthcare and pharmaceutical products. It operates in three segments, namely, Pharmaceuticals, Alcon (Eye Care), and Sandoz (Generics). The company has a broad range of access-to-medicine programs which include drug donations, selling at cost, social business initiatives, and patient assistance programs. In order to maintain its position, the company invests in R&D activities which help it to develop and launch new and advanced products.

In 2015, the company invested 18.1% of its total revenue on R&D activities, as compared to 17.4% in 2014. Novartis also focuses on acquisitions to sustain its strong presence in the market. For instance, in December 2016, Novartis acquired Ziarco Group Limited (U.K.), a privately held company focused on the development of novel treatments in dermatology. This acquisition strengthened Novartis’ dermatology portfolio and pipeline.

The overall growth strategies mapped from January 2013 to June 2017 include partnerships, agreements, collaborations, alliances, product launches and approvals, acquisitions, and expansions. Among these, product launches & product approvals and expansions were the key strategies adopted by industry players to achieve growth. Galderma S.A. (Switzerland), Valeant Pharmaceuticals International, Inc. (Canada), and Janssen Global Services LLC (U.S.) were some of the key players that adopted these strategies.

For instance, in December 2016, Galderma S.A received approval from the U.S. Food and Drug Administration (FDA) to market Restylane Refyne and Restylane Defyne. Similarly, in September 2016, Crescita Therapeutics Inc. received approval for its Pliaglis topical anesthetic cream for commercial sale in Mexico. In November 2014, Valeant Pharmaceuticals received an approval from the U.S. Food and Drug Administration for ONEXTON Gel (clindamycin phosphate and benzoyl peroxide), used as a once-daily treatment of comedonal and inflammatory acne.

You Can Also Talk to Our Research Experts for More Detailed Information@ http://bit.ly/2GGWE3B

Major Market Developments

• In January 2017, Johnson & Johnson entered into a definitive agreement to acquire Actelion, a Switzerland-based biotech company, for USD 30 billion. The acquisition gives J&J access to the Swiss group’s line of high-price, high-margin medicines for rare diseases.
• In December 2016, Novartis signed an agreement with Encore Vision, Inc. (U.S.) to acquire the latter’s clinical-stage, disease-modifying, topical treatment for presbyopia.
• In December 2016, Galderma received approval from the U.S. Food and Drug Administration (FDA) to market Restylane Refyne and Restylane Defyne.
• In December 2015, Valeant Pharmaceuticals signed an agreement with Walgreens (U.S.) with an aim to extend its distribution model to additional participating independent retail pharmacies.

Target Audience

• Hospitals and Private Clinics
• Ambulatory Surgery Centers (ASCs)
• Academic Institutes
• Medical Research Institutes
• Market Research and Consulting Firms
• Venture Capitalists
• Suppliers and Distributors of Topical Products

Read more:
https://www.marketsandmarkets.com/Market-Reports/topical-drug-delivery-market-124871717.html